Catherine A Hartzell

Title: Catherine A Hartzell: Innovator in Cancer Treatment

Introduction

Catherine A Hartzell is a prominent inventor based in Berkeley, CA (US). She has made significant contributions to the field of cancer treatment, particularly in the development of innovative therapies targeting prostate cancer. Her work has the potential to improve patient outcomes and advance the understanding of cancer immunotherapy.

Latest Patents

Catherine holds a patent for "Prostate cancer chimeric antigen receptors." This patent includes antibodies, fragments thereof, chimeric antigen receptors (CARs), and T cell receptors (TCRs) that comprise one or more of the anti-PMCA antigen binding domains. Additionally, it covers SynNotch receptors that include an anti-PSCA binding domain. The patent also provides polynucleotides encoding these antibodies, CARs, TCRs, and SynNotch receptors, along with compositions, cells, and cell therapies that utilize these innovations. Furthermore, it outlines methods of treatment that could significantly impact prostate cancer therapy.

Career Highlights

Catherine is currently associated with Kite Pharma, Inc., a company known for its focus on innovative cancer therapies. Her work at Kite Pharma has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research in cancer treatment.

Collaborations

Catherine has worked alongside notable colleagues, including Matthew Drever and Amy E Gilbert. Their collaborative efforts have furthered the development of advanced therapeutic strategies in oncology.

Conclusion

Catherine A Hartzell is a trailblazer in the field of cancer treatment, with her innovative patents and contributions to immunotherapy. Her work continues to inspire advancements in the fight against prostate cancer.